PRISM Stock IndexesCurrent Value% Change (Daily)% Change (Inception)Most ActiveTop % GainersTop % Losers
AdTech and Media$89.10-0.3%-10.9%SIRI 15,622 BBLR  10.729%DRCT -9.957%
Biotech$202.20-0.7%102.2%IBIO 3,893 BOLT  8.126%ADXN -17.022%
Cannabis$131.20-0.9%31.2%TLRY 29,660 CRLBF  2.488%HITI -5.608%
Consumer Products$86.102.2%-13.9%PTON 13,161 BOF  82.456%NUZE -13.333%
EV$76.60-1.5%-23.4%NKLA 94,973 INDI  6.334%LTHM -8.532%
Global Health$96.70-1.8%-3.3%ESPR 6,236 ATHE  8.879%VAXX -33.7%
Healthcare$83.50-1.3%-16.5%HIMS 5,120 DXR  2.791%PETV -6.173%
NextGen Tech & AI$88.00-0.7%-12.0%SOUN 64,626 SLNH  12.174%AVAI -30.159%
New Energy$79.50-0.4%-20.5%DNN 14,654 LTBR  3.6%MAXN -7.653%
MedDevices$92.60-1%-7.4%INBS 3,300 MDGS  10.28%SSII -10.27%
Mental Health$72.00-0.9%-28.0%BTAI 1,551 ABVC  9.63%BTAI -8.754%
Oil & Gas$99.50-0.5%-0.5%SWN 14,109 PHX  6.006%EP -8.624%
Pharmaceuticals$74.50-0.9%-25.5%TNXP 2,232 GLMD  10.681%HEPA -10.811%
Psychedelics$105.70-1.7%5.7%CYBN 5,436 PBM  5%LSDI -14.476%
Women’s Health$101.700%1.7%PDSB 930 AGRX  8.189%LPCN -7.5%
Zombie$89.50-0.6%-10.5%RIVN 45,654 BW  15.569%W -8.364%

Prism View

BranchOut Food Soars on Latest Deal with Nation’s Largest Retailer

Shares in disruptive food technology company, BranchOut Food (Nasdaq: BOF) soared more than 80% in morning trading on Wednesday after the company announced it had inked a third deal with one of the nation’s largest retailers. BranchOut Food stated that…

Update On Pending Merger Between Verde Bio and SensaSure Technologies

Oil and gas company Verde Bio (VBHI) issued an update regarding its pending merger with SensaSure Technologies (SSTC). In the update the company announced that the registration statement on Form S-4 has been declared effective by the Securities and Exchange…

Prism Stocks making the biggest moves premarket: Boeing, Tesla, Visa, Airbnb and more

Here's a look at the companies making waves ahead of the opening bell. Boeing — The aerospace giant's shares surged 3% as the company reported a smaller-than-anticipated loss in its recent quarterly results. The company noted an adjusted loss of…

Magnificent Seven’ Prepares to Announce Earnings Amid Market Recovery

Tesla Ends Week-Long Slide Before Earnings; Bond Market Stabilizes After $69 Billion Treasury Sale As tech…

Prism Stocks making the biggest moves midday: Spotify, JetBlue, Danaher, General Motors and more

Here's a midday summary of the key companies making financial headlines. General Motors saw a more…

It Takes More Than a Village to Raise a Successful Company: Village Farms (VFF) Continues to Gain National Share, up 71% YTD.

The Canadian cannabis company Village Farms International, Inc. (VFF) has returned 71% YTD, is up 26%…

Spotify jumps starts the spring with a gain

Spotify Technologies (NYSE: SPOT), a renowned audio-streaming platform, saw a notable rise in its share prices…

Stocks making the biggest premarket moves: General Motors, GE Aerospace, Novartis, JetBlue and more

General Motors — The automobile heavy-hitter experienced a 4% surge in its stock following a Q1…

M&A Moves: Matterport (MTTR) To Be Acquired By CoStar Group, Stock Up 176% On Report

Today the technology company specializing in creating immersive 3D experiences of physical spaces Matterport, Inc. (MTTR)…

Feature Story

High Stakes: Seven Key Drug Trial Failures in 2024

The cost of developing a new drug – a process that can take between 10 and 15 years from concept to market – has risen to approximately $2.3 billion, and there are many opportunities for failure along the way. Around 90% of drug candidates in clinical trials fail, despite significant investments in time and money.


Traders Lens


Shares of $WAB are hitting new all-time highs after the company released strong Q1 earnings as well as raising its guidance for 2024.

GeneDx Holdings Corp.

Genomics company $WGS is set to release earnings next week on April 29. The stock has been trading between about $8 and $12 over the past couple of months.

Lithium Americas Corp.

Shares of $LAC are down today after the company announced plans for a $55 million share offering. They plan to use the proceeds from the offering for the Thacker Pass lithium project in Nevada.

Bio View

Positive Results for Alto Neuroscience in Phase 1 Schizophrenia Study

Alto Neuroscience, Inc. (NYSE: ANRO) has announced positive results from its Phase 1 study of ALTO-101 for cognitive impairment associated with schizophrenia (CIAS). The study demonstrated favorable tolerability and improved pharmacokinetics of ALTO-101 when administered via a transdermal delivery system…

Silo Pharma Reports Positive Results from PTSD Study

Silo Pharma, Inc. (Nasdaq: SILO) has announced positive data from its recent pharmacokinetic (PK) study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD). Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia…

Reviva Pharmaceuticals’ Phase 3 Schizophrenia Program Receives FDA Acceptance

Reviva Pharmaceuticals (Nasdaq: RVPH) has received acceptance from the FDA for its 4-week registrational Phase 3 program for brilaroxazine in schizophrenia. Reviva’s RECOVER-2 study is a global Phase 3, randomized, double-blind, placebo-controlled, multicenter, 4-week trial designed to assess the safety…

Palisade Bio Collaboration to Advance Precision Medicine for Ulcerative Colitis

Biopharmaceutical company, Palisade Bio, Inc. (Nasdaq: PALI) has entered into a strategic collaboration with Strand Life…

FDA Places Hold on Neumora Schizophrenia Study

The FDA has placed a clinical hold on Neumora Therapeutics’ (Nasdaq: NMRA) Phase 1 trial of…

YS Biopharma to Initiate Hepatitis B Vaccine Trial in Philippines

Global biopharmaceutical company, YS Biopharma (Nasdaq: YS) has been granted clinical trial approval in the Philippines…

Nxera Pharma and Neurocrine Biosciences Complete Preclinical Toxicity Program in Schizophrenia Drug Hopeful

Nxera Pharma (OTC: SOLTF) and Neurocrine Biosciences (Nasdaq: NBIX) have successfully completed a long-term preclinical toxicity…
PRISM Indexes

BioMarin shares fall on slight revenue miss, despite EPS beat

The company’s total revenues saw a 9% increase year-over-year (YoY) to $648.8 million, with a notable 74% increase in VOXZOGO net product revenues, which reached… [Read More]